SGLT2 inhibitors confer cardiovascular, renal benefits in stage 4 CKM syndrome
31 Aug 2025
byJairia Dela Cruz
In the treatment of patients with stage 4 cardiovascular–kidney–metabolic (CKM) syndrome, sodium–glucose cotransporter 2 (SGLT2) inhibitors appear to exert cardio- and renoprotective effects, as shown in a retrospective study.
SGLT2 inhibitors confer cardiovascular, renal benefits in stage 4 CKM syndrome
31 Aug 2025